Formula Growth Ltd. Invests $2.22 Million in CareDx, Inc. $CDNA

Posted by on Aug 28th, 2026

Formula Growth Ltd. purchased a new position in shares of CareDx, Inc. (NASDAQ:CDNA – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 78,026 shares of the company’s stock, valued at approximately $2,224,000. Formula Growth Ltd. owned 0.15% of CareDx at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its position in CareDx by 18.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after buying an additional 170,504 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of CareDx by 11.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company’s stock valued at $2,378,000 after acquiring an additional 13,619 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of CareDx by 41.2% in the second quarter. JPMorgan Chase & Co. now owns 68,602 shares of the company’s stock valued at $1,340,000 after acquiring an additional 20,028 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of CareDx during the second quarter worth about $1,822,000. Finally, Nebula Research & Development LLC acquired a new position in shares of CareDx during the second quarter worth about $281,000.

Insider Transactions at CareDx

In related news, Director Christine Cournoyer sold 16,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $46.94, for a total value of $751,040.00. Following the completion of the transaction, the director directly owned 42,943 shares of the company’s stock, valued at $2,015,744.42. This trade represents a 27.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of CareDx stock in a transaction on Monday, June 29th. The stock was sold at an average price of $29.24, for a total value of $1,166,676.00. Following the transaction, the chief executive officer directly owned 661,959 shares of the company’s stock, valued at approximately $19,355,681.16. This represents a 5.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 114,936 shares of company stock worth $3,770,348 over the last quarter. Insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CDNA. Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 3rd. Weiss Ratings upgraded CareDx from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, August 13th. William Blair upgraded CareDx to a “hold” rating in a research report on Thursday, July 16th. BTIG Research increased their target price on CareDx from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Craig Hallum raised CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $47.75.

Check Out Our Latest Report on CDNA

CareDx Stock Up 2.7%

NASDAQ:CDNA opened at $52.36 on Friday. The firm’s fifty day simple moving average is $37.94 and its 200-day simple moving average is $26.27. The stock has a market cap of $2.71 billion, a PE ratio of 25.29 and a beta of 2.39. CareDx, Inc. has a fifty-two week low of $12.37 and a fifty-two week high of $53.67.

CareDx (NASDAQ:CDNA – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.23 by $0.14. CareDx had a net margin of 24.23% and a return on equity of 2.87%. The firm had revenue of $131.95 million during the quarter, compared to analysts’ expectations of $114.05 million. During the same quarter last year, the business earned ($0.16) earnings per share. The business’s revenue for the quarter was up 52.2% compared to the same quarter last year. Equities analysts anticipate that CareDx, Inc. will post 0.47 earnings per share for the current year.

CareDx Profile

(Free Report)

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.

Featured Stories

Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.